Soligenix (SNGX) Receivables - Other (2010 - 2024)
Soligenix's (SNGX) quarterly Receivables - Other came in at $3236.0 in Q4 2024, up 55.88% YoY from $2076.0 in Q1 2024, and up 212.17% on a QoQ basis from -$2885.0 in Q3 2024.
Soligenix (SNGX) Receivables - Other (2010 - 2024) Analysis & Trends
Soligenix (SNGX) has 8 years of Receivables - Other data on file, last reported at $3236.0 in Q4 2024.
- Quarterly Receivables - Other rose 55.88% year-over-year to $3236.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$48643.0 (changed 0.15% YoY) and the FY2024 annual result came in at -$48643.0, up 45.96% from the prior year.
- Receivables - Other improved to $3236.0 in Q4 2024, from -$2885.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $172000.0 in Q1 2022 to a low of -$327293.0 in Q1 2021.
- A 5-year average of $6467.7 and a median of $11939.0 in 2021 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2021 — Receivables - Other sank 675.71% — and 2022, when it soared 544.32%.
- Tracing SNGX's Receivables - Other over 5 years: stood at -$27088.0 in 2020, then jumped by 296.66% to $53272.0 in 2021, then sank by 110.25% to -$5462.0 in 2022, then jumped by 138.01% to $2076.0 in 2023, then soared by 55.88% to $3236.0 in 2024.
- The last three Receivables - Other figures came in at $3236.0 (Q4 2024), -$2885.0 (Q3 2024), and -$31615.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3,236.00 |
| Dec 31, 2024 | 3,236.00 |
| Sep 30, 2024 | -2,885.00 |
| Sep 30, 2024 | -2,885.00 |
| Jun 30, 2024 | -31,615.00 |
| Jun 30, 2024 | -31,615.00 |
| Mar 31, 2024 | -17,379.00 |
| Mar 31, 2024 | -17,379.00 |
| Dec 31, 2023 | 2,076.00 |
| Dec 31, 2023 | 2,076.00 |
| Sep 30, 2023 | 41,000.00 |
| Sep 30, 2023 | 41,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Jun 30, 2023 | 38,000.00 |
| Mar 31, 2023 | -98,456.00 |
| Mar 31, 2023 | -98,456.00 |
| Dec 31, 2022 | -5,462.00 |
| Dec 31, 2022 | -5,462.00 |
| Sep 30, 2022 | 123,000.00 |
| Sep 30, 2022 | 123,000.00 |